Opioid and cocaine combined effect on cocaine-induced changes in HPA and HPG axes hormones in men

Pharmacology Biochemistry and Behavior

Volumn 91, Issue 4, 2009, Pages 526-536

  Goletiani, Nathalie V ^a   Mendelson, Jack H ^a   Sholar, Michelle B ^a   Siegel, Arthur J ^a   Mello, Nancy K ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

ACTH; Cocaine; Cortisol; LH; Nalbuphine

Indexed keywords

COCAINE; CORTICOTROPIN; HYDROCORTISONE; LUTEINIZING HORMONE; NALBUPHINE; PLACEBO;

ADULT; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COCAINE DEPENDENCE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; ENDOCRINE FUNCTION; HORMONAL REGULATION; HORMONE DETERMINATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMIC PITUITARY GONADAL AXIS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LUTEINIZING HORMONE BLOOD LEVEL; MALE; NEUROENDOCRINE SYSTEM; NORMAL HUMAN; PRIORITY JOURNAL; REINFORCEMENT;

ADRENOCORTICOTROPIC HORMONE; ADULT; ANALGESICS, OPIOID; COCAINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; GONADAL STEROID HORMONES; GONADS; HORMONES; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LUTEINIZING HORMONE; MALE; NALBUPHINE; NARCOTIC ANTAGONISTS; TESTOSTERONE; YOUNG ADULT;

MACACA MULATTA;

EID: 58349110909     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.09.007     Document Type: Article

References (203)

1. Abs R., Verhelst J., Maeyaert J., Van Buyten J.P., Opsomer F., Adriaensen H., et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 85 (2000) 2215-2222
2. Abusada G.M., Abukhalaf I.K., Alford D.D., Vinzon-Bautista I., Pramanik A.K., Ansari N.A., et al. Solid-phase extraction and GC/MS quantitation of cocaine, ecgonine methyl ester, benzoylecgonine, and cocaethylene from meconium, whole blood, and plasma. J Anal Toxicol 17 (1993) 353-358
3. Adams M.L., Sewing B., Forman J.B., Meyer E.R., and Cicero T.J. Opioid-induced suppression of rat testicular function. J Pharmacol Exp Ther 266 (1993) 323-328
4. Adams M.L., Meyer E.R., and Cicero T.J. Interactions between alcohol- and opioid-induced suppression of rat testicular steroidogenesis in vivo. Alcohol Clin Exp Res 21 (1997) 684-690
5. Adrian J.R., Sanz Lipuzcoa J., Sanz Fernandez J., Olmos M., Ayesa M.A., and Arroyo J.L. A bupivacaine-morphine combination by intrathecal route: correlation between pain relief and postoperative neuroendocrine response. Rev Med Univ Navarra 32 (1988) 35-39
6. Aguilera G., Young W.S., Kiss A., and Bathia A. Direct regulation of hypothalamic corticotropin-releasing-hormone neurons by angiotensin II. Neuroendocrinology 61 (1995) 437-444
7. al-Damluji S., Bouloux P., White A., and Besser M. The role of alpha-2-adrenoceptors in the control of ACTH secretion; interaction with the opioid system. Neuroendocrinology 51 (1990) 76-81
8. Al-Damluji S., Perry L., Tomlin S., Bouloux P., Grossman A., Rees L.H., et al. Alpha-adrenergic stimulation of corticotropin secretion by a specific central mechanism in man. Neuroendocrinology 45 (1987) 68-76
9. Allolio B., Schulte H.M., Deuss U., Kallabis D., Hamel E., and Winkelman W. Effect of oral morphine and naloxone on pituitary-adrenal response in man induced by human corticotropin-releasing hormone. Acta Endocrinol (Copenh) 114 (1987) 509-514
10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed (2000), American Psychiatric Association, Washington, DC
11. Amini H., and Ahmadiani A. In vivo evidence for an increase in 5alpha-reductase activity in the rat central nervous system following morphine exposure. Int J Dev Neurosci 23 (2005) 621-626
12. Amir S., Brown Z.W., and Amit Z. The role of endorphins in stress: evidence and speculations. Neurosci Biobehav Rev 4 (1980) 77-86
13. Anand L.N., and Vijayan E. Studies on the effect of intratesticular administration of opioid peptides, naloxone or N-acetyl beta-endorphin antiserum on some testicular parameters in rats. Indian J Physiol Pharmacol 42 (1998) 107-112
14. Archer S., Glick S.D., and Bidlack J.M. Cyclazocine revisited. Physiol Behav 21 11 (1996) 1369-1373
15. Assenmacher I., Szafar A., Alonso G., Ixart G., and Barbanel G. Phyisology of neural pathways affecting CRH secretion. Ann NY Acad Sci 512 (1987) 149-161
16. Barraclough C.A., Wise P.M., and Selmanoff M.K. A Role for hypothalamic catecholamines in the regulation of gonadotropin secretion. Rec Prog Horm Res 40 (1984) 487-529
17. Barroso-Moguel R., Mendez-Armenta M., and Villeda-Hernandez J. Testicular lesions by chronic administration of cocaine in rats. J Appl Toxicol 1 (1994) 37-41
18. Bergman J., Kamien J.B., and Spealman R.D. Antagonism of cocaine self-administration by selective dopamine D1 and D2 antagonists. Behav Pharmacol 1 (1990) 355-363
19. Berul C.I., and Harclerode J.E. Effects of cocaine hydrochloride on the male reproductive system. Life Sci 45 (1989) 91-95
20. Blankstein J., Reyes F.I., Winter J.S., and Faiman C. Endorphins and the regulations of the human menstrual cycle. Clin Endocrinol (Oxf) 14 (1981) 287-294
21. Bliesener N., Albrecht S., Schwager A., Weckbecker K., Lichtermann D., and Klingmuller D. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab 90 (2005) 203-206
22. Bowen C.A., Negus S.S., Zong R., Neumeyer J.L., Bidlack J.M., and Mello N.K. Effects of mixed-action kappa-mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys. Neuropsychopharmacology 28 (2003) 1125-1139
23. Bracken M.B., Eskenazi B., Sachse K., McSharry J.E., Hellenbrand K., and Leo-Summers L. Association of cocaine use with sperm concentration, motility, and morphology. Fertil Steril 53 2 (1990) 315-322
24. Buckingham J.C., and Cooper T.A. Differences in hypothalamo-pituitary-adrenocortical activity in the rat after acute and prolonged treatment with morphine. Neuroendocrinology 38 (1984) 411-417
25. Butler P.D., Weiss J.M., Stout J.C., and Nemeroff C.B. Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. J Neuroscience 10 (1990) 176-183
26. Carnes M., Lent S.J., Goodman B., Mueller C., Saydoff J., and Erisman S. Effects of immunoneutralization of corticotropin-releasing hormone on ultradian rhythms of plasma adrenocorticotropin. Endocrinology 126 (1990) 1904-1913
27. Ceccarelli I., De Padova A.M., Fiorenzani P., Massafra C., and Aloisi A.M. Single opioid administration modifies gonadal steroids in both the CNS and plasma of male rats. Neuroscience 140 (2006) 929-937
28. Celani M.F., Carani C., Montanini V., Baraghini G.F., Zini D., Simoni M., et al. Further studies on the effects of heroin addiction on the hypothalamic-pituitary-gonadal function in man. Pharmacol Res Commun 16 (1984) 1193-1203
29. Chen W.P., Witkin J.W., and Silverman A.J. Gonadotropin releasing hormone (GnRH) neurons are directly innervated by catholamine terminals. Synapse 3 (1989) 288-290
30. Chen R., Osterhaus G., McKerchar T., and Fowler S.C. The role of exogenous testosterone in cocaine-induced behavioral sensitization and plasmalemmal or vesicular dopamine uptake in castrated rats. Neurosci Lett 51 3 (2003) 161-164
31. Chin J., Sternin O., Wu H.B., Burrell S., Lu D., Jenab S., et al. Endogenous gonadal hormones modulate behavioral and neurochemical responses to acute and chronic cocaine administration. Brain Res 945 (2002) 123-130
32. Chesnut C.H., Baylink D.J., and Nelp W.B. Stanozolol therapy in postmenopausal osteoporosis: preliminary results. Clin Res 26 (1979) 363A
33. Cicero T.J., Meyer E.R., Miller B.T., and Bell R.D. Age-related differences in the sensitivity of serum luteinizing hormone to prototypic mu, kappa and delta opiate agonists and antagonists. J Pharmacol Exp Ther 246 (1988) 14-20
34. Coiro V., Chiodera P., Rossi G., Volpi R., Salvi M., Camellini L., et al. Effect of naloxone on oxytocin-induced cortisol decrease in normal men. Acta Endocrinol (Copenh) 108 (1985) 261-265
35. Coiro V., Volpi R., Capretti L., Speroni G., Bianconi L., Cavazzini U., et al. 5-HT1-, but not 5-HT2-serotonergic, M1-, M2-muscarinic cholinergic or dopaminergic receptors mediate the ACTH/cortisol response to metoclopramide in man. Horm Res 33 (1990) 233-238
36. Coiro V., Cigarini C., Volpi R., Capretti L., Bacchi-Modena A., and Chiodera P. Naloxone enhances angiotensin II-induced increase in serum luteinizing hormone concentrations in normal women. Regul Pept 51 (1994) 161-167
37. Condon T.P., Ronnekleiv O.K., and Kelly M.J. Estrogen modulation of the alpha-1-adrenergic response of hypothalamic neurons. Neuroendocrinology 50 (1989) 51-58
38. Dackis C.A., and Gold M.S. Psychopharmacology of cocaine. Psychiatr Ann 18 (1988) 528-530
39. Degli Uberti E.C., Petraglia F., Trasforini G., Salvadori S., Margutti A., Bianconi M., et al. Dermorphin reduces the metyrapone-evoked release of adrenocorticotropin, beta-endorphin, and beta-lipotropin in man. J Clin Endocrinol Metab 61 (1985) 1018-1022
40. Delitala G., Devilla L., and Di Biaso D. Dopamine inhibits the naloxone induced gonadotrophin rise in man. Clin Endocrinol (Oxf) 13 (1980) 515-518
41. Delitala G., Devilla L., and Arata L. Opiate receptors and anterior pituitary hormone secretion in man. Effect of naloxone infusion. Acta Endocrinol (Copenh) 97 (1981) 150-156
42. Delitala G., Grossman A., and Besser M. Differential effects of opiate peptides and alkaloids on anterior pituitary hormone secretion. Neuroendocrinology 37 (1983) 275-279
43. Delitala G., Palermo M., Tomasi P., Besser M., and Grossman A. Adrenergic stimulation of the human pituitary-adrenal axis is attenuated by an analog of met-enkephalin. Neuroendocrinology 53 (1991) 41-46
44. Delitala G., Trainer P.J., Oliva O., Fanciulli G., and Grossman A.B. Opioid peptide and alpha-adrenoceptor pathways in the regulation of the pituitary-adrenal axis in man. J Endocrinol 141 (1994) 163-168
45. Dimitrov E.L., DeJoseph M.R., Brownfield M.S., and Urban J.H. Involvement of neuropeptide Y Y1 receptors in the regulation of neuroendocrine corticotropin-releasing hormone neuronal activity. Endocrinology 148 (2007) 3666-3673
46. Ehrenreich H., Kolmar C., Muller O.A., and Goebel F.D. Potentiation of the hCRF-induced release of ACTH in man by an opioid antagonist. Klin Wochenschr 65 (1987) 453-457
47. Elias A.N., Kyaw T., Stone S., Weathersbee P., Iyer K., and Ascher M.S. Interaction between gabaergic and opioid pathways in the regulation of gonadotropin secretion in males. Horm Metab Res 18 (1986) 838-841
48. Ellingboe J., Veldhuis J.D., Mendelson J.H., Kuehnle J.C., and Mello N.K. Effect of endogenous opioid blockade on the amplitude and frequency of pulsatile luteinizing hormone secretion in normal men. J Clin Endocrinol Metab 54 (1982) 854-857
49. Emanuele M.A., LaPaglia N., Steiner J., Jabamoni K., Hansen M., Kirsteins L., et al. Reversal of ethanol-induced testosterone suppression in peripubertal male rats by opiate blockade. Alcohol Clin Exp Res 22 (1998) 1199-1204
50. Esposti D., Lissoni P., Mauri R., Rovelli F., Orsenigo L., Pescia S., et al. The pineal gland-opioid system relation: melatonin-naloxone interactions in regulating GH and LH releases in man. J Endocrinol Invest 11 (1988) 103-106
51. Evans S.M., and Foltin R.W. Pharmacokinetics of repeated doses of intravenous cocaine across the menstrual cycle in rhesus monkeys. Pharmacol Biochem Behav 83 (2006) 56-66
52. Festa E.D., Jenab S., Chin J., Gazi F.M., Wu H.B., Russo S.J., et al. Frequency of cocaine administration affects behavioral and endocrine responses in male and female Fischer rats. Cell Mol Biol (Noisy-le-grand) 49 (2003) 1275-1280
53. Folli D., Mutti A., Van der Venne M.T., Berlin A., Gerra G., Cavazzini S., et al. Neuroendocrine response to psychological performance testing. Psychoneuroendocrinology 17 (1992) 467-474
54. Foresta C., Marra S., Scanelli G., and Scandellari C. Gonadal steroids and opioid control of gonadotropin secretion in man. Fertil Steril 40 (1983) 798-801
55. Foresta C., Scanelli G., Tramarin A., and Scandellari C. Serotonin but not dopamine is involved in the naloxone-induced luteinizing hormone release in man. Fertil Steril 43 (1985) 447-450
56. Foresta C., Mioni R., and Scandellari C. Evidence for serotoninergic system involvement in opioid control of luteinizing hormone secretion in man. Clin Endocrinol (Oxf) 25 (1986) 573-578
57. Fuller R.W. The involvement of serotonin in regulation of pituitary-adrenocortical function. Front Neuroendocrinol 13 (1992) 250-270
58. Gambacciani M., Liu J.H., Swartz W.H., Tueros V.S., Rasmussen D.D., and Yen S.S. Intrinsic pulsatility of ACTH release from the human pituitary in vitro. Clin Endocrinol (Oxf) 26 (1987) 557-563
59. Gawin F.H. Chronic neuropharmacology of cocaine: progress in pharmacotherapy. J Clin Psychiatry 49 Suppl (1988) 11-16
60. Geer E.B., Landman R.E., Wardlaw S.L., Conwell I.M., and Freda P.U. Stimulation of the hypothalamic-pituitary-adrenal axis with the opioid antagonist nalmefene. Pituitary 8 (2005) 115-122
61. Genazzani A.R., Genazzani A.D., Volpogni C., Pianazzi F., Li G.A., Surico N., et al. Opioid control of gonadotrophin secretion in humans. Hum Reprod 8 Suppl 2 (1993) 151-153
62. George V.K., Li H., Teloken C., Grignon D.J., Lawrence W.D., and Dhabuwala C.B. Effects of long-term cocaine exposure on spermatogenesis and fertility in peripubertal male rats. J Urol 155 1 (1996) 327-331
63. Gerra G., Baldaro B., Zaimovic A., Moi G., Bussandri M., Raggi M.A., et al. Neuroendocrine responses to experimentally-induced emotions among abstinent opioid-dependent subjects. Drug Alcohol Depend 71 (2003) 25-35
64. Gharagozlou P., Demirci H., David Clark J., and Lameh J. Activity of opioid ligands in cells expressing cloned mu opioid receptors. BMC Pharmacol 3 (2003) 1
65. Giordano R., Pellegrino M., Picu A., Bonelli L., Balbo M., Berardelli R., et al. Neuroregulation of the hypothalamus-pituitary-adrenal (HPA) axis in humans: effects of GABA-, mineralocorticoid-, and GH-secretagogue-receptor modulation. ScientificWorldJournal 6 (2006) 1-11
66. Goeders N.E. A neuroendocrine role in cocaine reinforcement. Psychoneuroendocrinology 22 (1997) 237-259
67. Goeders N.E. Stress and cocaine addiction. J Pharmacol Exp Ther 301 (2002) 785-789
68. Goeders N.E. The HPA axis and cocaine reinforcement. Psychoneuroendocrinology 27 (2002) 13-33
69. Goeders N.E., and Guerin G.F. Role of corticosterone in intravenous cocaine self-administration in rats. Neuroendocrinology 64 (1996) 337-348
70. Goeders N.E., and Guerin G.F. Effects of the CRH receptor antagonist CP-154,526 on intravenous cocaine self-administration in rats. Neuropsychopharmacology 23 (2000) 577-586
71. Gold M.S., Pottash A.L., Extein I., Martin D.A., Finn L.B., Sweeney D.R., et al. Evidence for an endorphin dysfunction in methadone addicts: lack of ACTH response to naloxone. Drug Alcohol Depend 8 (1981) 257-262
72. Goletiani N.V., Mendelson J.H., Sholar M.B., Siegel A.J., Skupny A., and Mello N.K. Effects of nalbuphine on anterior pituitary and adrenal hormones and subjective responses in male cocaine abusers. Pharmacol Biochem Behav 86 (2007) 667-677
73. Gopalan C., Gilmore D.P., and Brown C.H. Effects of different opiates on hypothalamic monoamine turnover and on plasma LH levels in pro-oestrous rats. J Neurol Sci 94 (1989) 211-219
74. Grey G.D., Smith E.R., Damassa D.A., Ehrenkranz J.R.L., and Davidson J.M. Neuroendocrine mechanisms mediating the suppression of circulating testosterone levels associated with chronic stress in male rats. Neuroendocrinology 25 (1978) 247-256
75. Grossman A. Brain opiates and neuroendocrine function. Clin Endocrinol Metab 12 (1983) 725-746
76. Grossman A., Moult P.J., Cunnah D., and Besser M. Different opioid mechanisms are involved in the modulation of ACTH and gonadotrophin release in man. Neuroendocrinology 42 (1986) 357-360
77. Grossman A., Moult P.J., Gaillard R.C., Delitala G., Toff W.D., Rees L.H., et al. The opioid control of LH and FSH release: effects of a met-enkephalin analogue and naloxone. Clin Endocrinol (Oxf) 14 (1981) 41-47
78. Hall J.E. Neuroendocrine control of the menstrual cycle. In: Strauss III J.F., and Barbieri R.L. (Eds). Yen and Jaffe's reproductive endocrinology: physiology, pathophysiology, and clinical management (2004), Elsevier Saunders, Philadelphia 195-211
79. Hallinan R., Byrne A., Agho K., McMahon C., Tynan P., and Attia J. Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. J Sex Med 5 (2008) 684-692
80. Heesch C.M., Negus B.H., Bost J.E., Keffer J.H., Snyder II R.W., and Eichhorn E.J. Effects of cocaine on anterior pituitary and gonadal hormones. J Pharmacol Exp Ther 278 (1996) 1195-1200
81. Hernandez-Avila C.A., Wand G., Luo X., Gelernter J., and Kranzler H.R. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet B Neuropsychiatr Genet 118 (2003) 60-65
82. Hu M., and Becker J.B. Effects of sex and estrogen on behavioral sensitization to cocaine in rats. J Neurosci 23 (2003) 693-699
83. Hu M., Crombag H.S., Robinson T.E., and Becker J.B. Biological basis of sex differences in the propensity to self-administer cocaine. Neuropsychopharmacology 29 (2004) 81-85
84. Jackson L.R., Robinson T.E., and Becker J.B. Sex differences and hormonal influences on acquisition of cocaine self-administration in rats. Neuropsychopharmacology 31 (2006) 129-138
85. Johanson C.E., and Fischman M.W. The pharmacology of cocaine related to its abuse. Pharmacol Rev 41 1 (1989(Mar):3-52) 3-52
86. Johnson M.D., Crowley W.R., and Carroll B. Role of central serotonin systems in the stimulatory effects of ovarian hormones and naloxone on luteinizing hormone release in female rats. Endocrinology 118 (1986) 1180-1186
87. Kakko J., von Wachenfeldt J., Svanborg K.D., Lidstrom J., Barr C.S., and Heilig M. Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence. Biol Psychiatry 63 (2008) 172-177
88. Kleber H.D., and Gawin F.H. Cocaine abuse: a review of current and experimental treatments. In: Grabowski J. (Ed). Cocaine: pharmacology, effects, and treatment of abuse. NIDA research monograph, 50 (1984), Government Printing Office, Washington, D.C. 111-129 [DHHS publication no. (ADM) 87-1326.]
89. Koenig J.I. Pituitary gland: neuropeptides, neurotransmitters and growth factors. Toxicol Pathol 17 (1989) 256-265
90. Kostic T., Andric S., Kovacevic R., and Maric D. The effect of opioid antagonists in local regulation of testicular response to acute stress in adult rats. Steroids 62 (1997) 703-708
91. Kuhn J.M., and Saltiel H. Role of endogenous opioid peptides in the regulation of pituitary secretions. Ann Endocrinol (Paris) 47 (1986) 97-105
92. Leadem C.A., and Kalra S.P. Effects of endogenous opioid peptides and opiates on luteinizing hormone and prolactin secretion in ovariectomized rats. Neuroendocrinology 41 (1985) 342-352
93. Leadem C.A., and Yagenova S.V. Effects of specific activation of mu-, delta- and kappa-opioid receptors on the secretion of luteinizing hormone and prolactin in the ovariectomized rat. Neuroendocrinology 45 (1987) 109-117
94. Leadem C.A., Crowley W.R., Simpkins J.W., and KAlra S.P. Effects of naloxone on catecholamine and LHRN release from the perifused hypothalamus of the steroid primed rat. Neuroendocrinology 40 (1985) 497-500
95. Leposavic G., Cover P.O., and Buckingham J.C. In vivo and in vitro studies on the opioidergic control of the secretion of gonadotrophin-releasing hormone and luteinizing hormone in sexually immature and adult male rats. Neuroendocrinology 53 (1991) 579-588
96. Limone P., Calvelli P., Altare F., Ajmone-Catt P., Lima T., and Molinatti G.M. Evidence for an interaction between alpha-MSH and opioids in the regulation of gonadotropin secretion in man. J Endocrinol Invest 20 (1997) 207-210
97. Mantsch J.R., Saphier D., and Goeders N.E. Corticosterone facilitates the acquisition of cocaine self-administration in rats: opposite effects of the type II glucocorticoid receptor agonist dexamethasone. J Pharmacol Exp Ther 287 (1998) 72-80
98. Mantsch J.R., Schlussman S.D., Ho A., and Kreek M.J. Effects of cocaine self-administration on plasma corticosterone and prolactin in rats. J Pharmacol Exp Ther 294 (2000) 239-247
99. Marko M., and Romer D. Inhibitory effect of a new opioid agonist on reproductive endocrine activity in rats of both sexes. Life Sci 33 (1983) 233-240
100. Martin del Campo A.F., Dowson J.H., Herbert J., and Paykel E.S. Effects of naloxone on diurnal rhythms in mood and endocrine function: a dose-response study in man. Psychopharmacology (Berl) 114 (1994) 583-590
101. Mello N.K., and Mendelson J.H. Drug therapy: management of cocaine abuse and dependence. New Engl. J. Med. 334 (1996) 965-972
102. Mello N.K., and Negus S.S. Interactions between kappa opioid agonists and cocaine: Preclinical studies. In: Glick S.D., and Maisonneuve I.M. (Eds). The Archer conference on drug abuse: new medications (2000), New York Academy of Sciences, New York 104-132
103. Mello N.K., and Mendelson J.H. Cocaine, hormones, and behavior: clinical and preclinical studies. Horm, Brain Behav 5 (2002) 665-745
104. Mello N.K., Mendelson J.H., Bree M.P., Kelly M.L., and Drieze J.M. Cocaine stimulates LH and decreases PRL in female rhesus monkeys. NIDA Res Monogr 95 (1989) 337-338
105. Mello N.K., Mendelson J.H., Bree M.P., and Skupny A. Naltrexone effects on pituitary and gonadal hormones in male and female rhesus monkeys. Pharmacol Biochem Behav 31 (1988) 683-691
106. Mello N.K., Mendelson J.H., Drieze J., and Kelly M. Cocaine effects on luteinizing hormone-releasing hormone-stimulated anterior pituitary hormones in female rhesus monkey. J Clin Endocrinol Metab 71 (1990) 1434-1441
107. Mello N.K., Mendelson J.H., Drieze J., and Kelly M. Acute effects of cocaine on prolactin and gonadotropins in female rhesus monkey during the follicular phase of the menstrual cycle. J Pharmacol Exp Ther 254 (1990) 815-823
108. Mello N.K., Kamien J.B., Lukas S.E., Drieze J., and Mendelson J.H. The effects of nalbuphine and butorphanol treatment on cocaine and food self-administration by rhesus monkeys. Neuropsychopharmacology 8 (1993) 45-55
109. Mello N.K., Sarnyai Z., Mendelson J.H., Drieze J.M., and Kelly M. Acute effects of cocaine on anterior pituitary hormones in male and female rhesus monkeys. J Pharmacol Exp Ther 266 (1993) 804-811
110. Mello N.K., Mendelson J.H., and Kelly M. Acute effects of nalmefene on LH, prolactin, and testosterone in male rhesus monkeys. Pharmacol Biochem Behav 66 (2000) 275-283
111. Mello N.K., Mendelson J.H., Negus S.S., Kelly M., Knudson I., and Roth M.E. The effects of cocaine on gonadal steroid hormones and LH in male and female rhesus monkeys. Neuropsychopharmacology 29 (2004) 2024-2034
112. Mello N.K., Mendelson J.H., Sholar M.B., Jaszyna-Gasior M., Goletiani N., and Siegel A.J. Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men. Neuropsychopharmacology 30 (2005) 618-632
113. Mendelson J.H. Plasma prolactin levels and cocaine abuse. Am J Psychiatry 148 (1991) 397
114. Mendelson J.H., and Mello N.K. Plasma testosterone levels during chronic heroin use and protracted abstinence. A study of Hong Kong addicts. Clin Pharmacol Ther 17 (1975) 529-533
115. Mendelson J.H., and Mello N.K. Hormones and psycho-sexual development in young men following chronic heroin use. Neurobehav Toxicol Teratol 4 (1982) 441-445
116. Mendelson J.H., Mendelson J.E., and Patch V.D. Plasma testosterone levels in heroin addiction and during methadone maintenance. J Pharmacol Exp Ther 192 (1975) 211-217
117. Mendelson J.H., Meyer R.E., Ellingboe J., Mirin S.M., and McDougle M. Effects of heroin and methadone on plasma cortisol and testosterone. J Pharmacol Exp Ther 195 (1975) 296-302
118. Mendelson J.H., Inturrisi C.E., Renault P., and Senay E.C. Effects of acetylmethadol on plasma testosterone. Clin Pharmacol Ther 19 (1976) 371-374
119. Mendelson J.H., Ellingboe J., Kuehnle J., and Mello N.K. Heroin and naltrexone effects on pituitary-gonadal hormones in man: tolerance and supersensitivity. NIDA Res Monogr 27 (1979) 302-308
120. Mendelson J.H., Ellingboe J., Kuehnle J.C., and Mello N.K. Heroin and naltrexone effects on pituitary-gonadal hormones in man: interaction of steroid feedback effects, tolerance and supersensitivity. J Pharmacol Exp Ther 214 (1980) 503-506
121. Mendelson J.H., Ellingboe J., Mello N.K., and Kuehnle J. Buprenorphine effects on plasma luteinizing hormone and prolactin in male heroin addicts. J Pharmacol Exp Ther 220 (1982) 252-255
122. Mendelson J.H., Cristofaro P., Mello N.K., Skupny A.S., Ellingboe J., and Benedikt R. Endogenous opioid modulation of luteinizing hormone, prolactin, and estradiol in women: interactions with ethanol. NIDA Res Monogr 67 (1986) 112-118
123. Mendelson J.H., Mello N.K., Cristofaro P., Ellingboe J., Skupny A., Palmieri S.L., et al. Alcohol effects on naloxone-stimulated luteinizing hormone, prolactin and estradiol in women. J Stud Alcohol 48 (1987) 287-294
124. Mendelson J.H., Teoh S.K., Lange U., Mello N.K., Weiss R., Skupny A., et al. Anterior pituitary, adrenal, and gonadal hormones during cocaine withdrawal. Am J Psychiatry 145 (1988) 1094-1098
125. Mendelson J.H., Mello N.K., Teoh S.K., Ellingboe J., and Cochin J. Cocaine effects on pulsatile secretion of anterior pituitary, gonadal, and adrenal hormones. J Clin Endocrinol Metab 69 (1989) 1256-1260
126. Mendelson J.H., Weiss R., Griffin M., Mirin S.M., Teoh S.K., Mello N.K., et al. Some special considerations for treatment of drug abuse and dependence in women. NIDA Res Monogr 106 (1991) 313-327
127. Mendelson J.H., Teoh S.K., Mello N.K., Ellingboe J., and Rhoades E. Acute effects of cocaine on plasma adrenocorticotropic hormone, luteinizing hormone and prolactin levels in cocaine-dependent men. J Pharmacol Exp Ther 263 (1992) 505-509
128. Mendelson J.H., Sholar M., Mello N.K., Teoh S.K., and Sholar J.W. Cocaine tolerance: behavioral, cardiovascular, and neuroendocrine function in men. Neuropsychopharmacology 18 (1998) 263-271
129. Mendelson J.H., Sholar M.B., Siegel A.J., and Mello N.K. Effects of cocaine on luteinizing hormone in women during the follicular and luteal phases of the menstrual cycle and in men. J Pharmacol Exp Ther 296 (2001) 972-979
130. Mendelson J.H., and Mello N.K. Cocaine and other commonly abused drugs. In: Fauci A.S., Braunwald E., Kasper D.L., Hauser S.L., Longo D.L., Jameson J.L., and Loscalzo J. (Eds). Harrison's principles of internal medicine. 17th Edition (2008), The McGraw-Hill Companies, Inc., New York 2733-2736
131. Mendelson J.H., Mello N.K., Sholar M.B., Siegel A.J., Mutschler N., and Halpern J. Temporal concordance of cocaine effects on mood states and neuroendocrine hormones. Psychoneuroendocrinology 27 (2002) 71-82
132. Mendelson J.H., Sholar M.B., Mutschler N.H., Jaszyna-Gasior M., Goletiani N.V., Siegel A.J., et al. Effects of intravenous cocaine and cigarette smoking on luteinizing hormone, testosterone and prolactin in men. J Pharmacol Exp Ther 307 (2003) 339-348
133. Mershon J.L., Sehlhorst C.S., Rebar R.W., and Liu J.H. Evidence of a corticotropin-releasing hormone pulse generator in the macaque hypothalamus. Endocrinology 130 (1992) 2991-2996
134. Millman R. Evaluation and clinical management of cocaine abusers. J Clin Psychiatry 49 Suppl (1988) 27-33
135. Mirin S.M., Mendelson J.H., Ellingboe J., and Meyer R.E. Acute effects of heroin and naltrexone on testosterone and gonadotropin secretion: a pilot study. Psychoneuroendocrinology 1 (1976) 359-369
136. Mirin S.M., Meyer R.E., Mendelson J.H., and Ellingboe J. Opiate use and sexual function. Am J Psychiatry 137 (1980) 909-915
137. Morley J.E. Neuroendocrine effects of endogenous opioid peptides in human subjects: a review. Psychoneuroendocrinology 8 (1983) 361-379
138. Negus S.S., and Mello N.K. Effects of mu-opioid agonists on cocaine- and food-maintained responding and cocaine discrimination in rhesus monkeys: role of mu-agonist efficacy. J Pharmacol Exp Ther 300 (2002) 1111-1121
139. Neumeyer J.L., Bidlack J.M., Zong R., Bakthavachalam V., Gao P., Cohen D.J., et al. Synthesis and opioid receptor affinity of morphinan and bezomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence. J Med Chem (2000) 114-122
140. Neumeyer J.L., Mello N.K., Negus S.S., and Bidlack J.M. Kappa opioid agonists as targets for pharmacotherapies in cocaine abuse. Pharm Acta Helv (2000) 337-344
141. PDR. Physicians desk reference. 58th Edition (2005), Thomson PDR, Montvale, NJ
142. Pende A., Musso N.R., Montaldi M.L., Pastorino G., Arzese M., and Devilla L. Evaluation of the effects induced by four opiate drugs, with different affinities to opioid receptor subtypes, on anterior pituitary LH, TSH, PRL and GH secretion and on cortisol secretion in normal men. Biomed Pharmacother 40 (1986) 178-182
143. Petraglia F., Locatelli V., Facchinetti F., Bergamaschi M., Genazzani A.R., and Cocchi D. Oestrous cycle-related LH responsiveness to naloxone: effect of high oestrogen levels on the activity of opioid receptors. J Endocrinol 108 (1986) 89-94
144. Pfeiffer A., and Herz A. Endocrine actions of opioids. Horm Metab Res 16 (1984) 386-397
145. Pfeiffer A., Herz A., Loriaux D.L., and Pfeiffer D.G. Central kappa- and mu-opiate receptors mediate ACTH-release in rats. Endocrinology 116 (1985) 2688-2690
146. Pfeiffer A., Knepel W., Braun S., Meyer H.D., Lohmann H., and Brantl V. Effects of a kappa-opioid agonist on adrenocorticotropic and diuretic function in man. Horm Metab Res 18 (1986) 842-848
147. Pfeiffer D.G., Pfeiffer A., Almeida O.F., and Herz A. Opiate suppression of LH secretion involves central receptors different from those mediating opiate effects on prolactin secretion. J Endocrinol 114 (1987) 469-476
148. Plotsky P.M. Opioid inhibition of immunoreactive corticotropin-releasing factor secretion into the hypophysial-portal circulation of rats. Regul Pept 16 (1986) 235-242
149. Plotsky P., Cunningham E.T.J., and Widmaiere E.p. Catecholaminergic modulation of corticotropin-releasing factor and andrenocorticotropin secretion. Endocrine Rev 10 (1989) 437-458
150. Preston K.L., and Bigelow G.E. Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination. J Pharmacol Exp Ther 295 (2000) 114-124
151. Preston K.L., Umbricht A., Schroeder J.R., abreu M.E., Epstein D.H., and Pickworth W.B. Cyclazocine: comparison to hydromorphone and interaction with cocaine. Behav Pharmacol (2004) 91-102
152. Quiñones-Jenab V. Why are women from Venus and men from Mars when they abuse cocaine? Brain Res 2006;1126(1)(Dec 18):200-3.
153. Quiñones-Jenab V., Perrotti L.I., Mc Monagle J., Ho A., and Kreek M.J. Ovarian hormone replacement affects cocaine-induced behaviors in ovariectomized female rats. Pharmacol Biochem Behav 67 3 (2000) 417-422
154. Quiñones-Jenab V, Perrotti LI, Ho A, Jenab S, Schlussman SD, Franck J, Kreek MJ. Cocaine affects progesterone plasma levels in female rats. Pharmacol Biochem Behav 2000b;66(2)(Jun):449-53.
155. Quiñones-Jenab V, Krey LC, Schlussman SD, Ho A, Kreek MJ. Chronic 'binge' pattern cocaine alters the neuroendocrine profile of pregnant rats. Neurosci Lett 2000c;282(1-2)(Mar 17):120-2.
156. Rajagopal A., Vassilopoulou-Sellin R., Palmer J.L., Kaur G., and Bruera E. Hypogonadism and sexual dysfunction in male cancer survivors receiving chronic opioid therapy. J Pain Symptom Manage 26 (2003) 1055-1061
157. Rivier C., and Vale W. Cocaine stimulates adrenocorticotropin (ACTH) secretion through a corticotropin-releasing factor (CRF)-mediated mechanism. Brain Res 422 (1987) 403-406
158. Rivier C., and Rivest S. Effect of stress on the activity of the hypothalamic-pituitary-gonadal axis: peripheral and central mechanisms. Biol Reprod (1991) 523-532
159. Roberts L.J., Finch P.M., Pullan P.T., Bhagat C.I., and Price L.M. Sex hormone suppression by intrathecal opioids: a prospective study. Clin J Pain 18 (2002) 144-148
160. Rodriguez M.C., Sanchez-Yague J., and Paniagua R. Effects of cocaine on testicular structure in the rat (published erratum appears in Reprod. Toxicol., 1992; 6(3):283). Reprod Toxicol 6 (1992) 51-55
161. Ropert J.F., Quigley M.E., and Yen S.S. Endogenous opiates modulate pulsatile luteinizing hormone release in humans. J Clin Endocrinol Metab 52 (1981) 583-585
162. Rossmanith W.G., and Yen S.S. Sleep-associated decrease in luteinizing hormone pulse frequency during the early follicular phase of the menstrual cycle: evidence for an opioidergic mechanism. J Clin Endocrinol Metab 65 (1987) 715-718
163. Rossmanith W.G., and Wirth U. Effects of sleep on gonadotropin secretion. Geburtshilfe Frauenheilkd 53 (1993) 735-741
164. Rossmanith W.G., Mortola J.F., and Yen S.S. Role of endogenous opioid peptides in the initiation of the midcycle luteinizing hormone surge in normal cycling women. J Clin Endocrinol Metab 67 (1988) 695-700
165. Rossmanith W.G., Wirth U., Sterzik K., and Yen S.S. The effects of prolonged opioidergic blockade on LH pulsatile secretion during the menstrual cycle. J Endocrinol Invest 12 (1989) 245-252
166. Rubin R.T., Rhodes M.E., Miller T.H., Jakab R.L., and Czambel R.K. Sequence of pituitary-adrenal cortical hormone responses to low-dose physostigmine administration in young adult women and men. Life Sci 79 (2006) 2260-2268
167. SAMHSA. Substance abuse and mental health services administration. Results from the 2006 National Survey on Drug Use and Health: National Findings. Washington, DC: SAMHSA's Health Information Network; 2006.
168. Samuels L.T., Henschel A.F., and Keys A. Influence of methyltestosterone on muscular work and creatine metabolism in normal young men. J Clin Endocrinol 2 (1942) 649-654
169. Sarnyai Z., Dhabhar F.S., McEwen B.S., and Kreek M.J. Neuroendocrine-related effects of long-term, 'binge' cocaine administration: diminished individual differences in stress-induced corticosterone response. Neuroendocrinology 68 (1998) 334-344
170. Sarnyai Z., Mello N.K., Mendelson J.H., Eros-Sarnyai M., and Mercer G. Effects of cocaine on pulsatile activity of the hypothalamic-pituitary-adrenal axis in male rhesus monkeys: neuroendocrine and behavioral correlates. J Pharmacol Exp Ther (1996)
171. Saso L. Effects of drug abuse on sexual response. Ann Ist Super Sanita 38 (2002) 289-296
172. Schluger J.H., Ho A., Borg L., Porter M., Maniar S., Gunduz M., et al. Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. Alcohol Clin Exp Res 22 (1998) 1430-1436
173. Schroeder J.P., and Packard M.G. Role of dopamine receptor subtypes in the acquisition of a testosterone conditioned place preference in rats. Neurosci Lett 282 1-2 (2000) 17-20
174. Sherwin B.B., and Gelfand M.M. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 151 (1985) 153-160
175. Sholar M.B., Mendelson J.H., Mello N.K., Siegel A.J., Kaufman M.J., Levin J.M., et al. Concurrent pharmacokinetic analysis of plasma cocaine and adrenocorticotropic hormone in men. J Clin Endocrinol Metab 83 (1998) 966-968
176. Siegel R.A., and Revesz L. Effects of the novel opiate antagonist, SDZ 210-096, on luteinizing hormone secretion in the rat. J Pharmacol Exp Ther 249 (1989) 264-270
177. Sikharulidze Z.D., Kopaliani M.G., and Kilasoniia L.O. Comparative evaluation of clinical symptoms and status of bone metabolism in patients with heroin and buprenorphine addiction in the period of withdrawal. Georgian Med News (2006) 72-76
178. Singh H.H., Purohit V., and Ahluwalia B.S. Methadone blocks dopamine-mediated release of gonadotropins in rat hypothalamus. Neuroendocrinology 34 (1982) 347-352
179. Smith Y.R., Zubieta J.K., del Carmen M.G., Dannals R.F., Ravert H.T., Zacur H.A., et al. Brain opioid receptor measurements by positron emission tomography in normal cycling women: relationship to luteinizing hormone pulsatility and gonadal steroid hormones. J Clin Endocrinol Metab 83 (1998) 4498-4505
180. Snowden E.U., Khan-Dawood F.S., and Dawood M.Y. The effect of naloxone on endogenous opioid regulation of pituitary gonadotropins and prolactin during the menstrual cycle. J Clin Endocrinol Metab 59 (1984) 298-302
181. Spealman R.D., Bergman J., Madras B.K., Kamien J.B., and Melia K.F. Role of D1 and D2 dopamine receptors in the behavioral effects of cocaine. Neurochem Int 20 Suppl (1992;20(Suppl):147S-52S) 147S-152S
182. Spremovic-Radjenovic S., Popovic V., Matijasevic S., Lazovic G., and Petkovic S. Effect of opioids and gamma-aminobutyric acid on ovulation. Srp Arh Celok Lek 125 (1997) 329-332
183. Steele P.A., and Judd S.J. Role of endogenous opioids in reducing the frequency of pulsatile luteinizing hormone secretion induced by progesterone in normal women. Clin Endocrinol (Oxf) 25 (1986) 669-674
184. Suda T., Tozawa F., Iwai I., Sato Y., Sumitomo T., Nakano Y., et al. Neuropeptide Y increases the corticotropin-releasing factor messenger ribonucleic acid level in the rat hypothalamus. Brain Res Mol Brain Res 18 (1993) 311-315
185. Taleisnik S., and Sawyer C.H. Activation of the CNS noradrenergic system may inhibit as well as facilitate pituitary luteinizing hormone release. Neuroendocrinology 44 (1986) 265-268
186. Taylor W.N. Synthetic anabolic androgenic steroids: a plea for controlled substance status. Phys Sports Med 15 (1987) 140-151
187. Teoh S.K., Mendelson J.H., Mello N.K., and Skupny A. Alcohol effects on naltrexone-induced stimulation of pituitary, adrenal, and gonadal hormones during the early follicular phase of the menstrual cycle. J Clin Endocrinol Metab 66 (1988) 1181-1186
188. van Haaren F., and Meyer M.E. Sex differences in locomotor activity after acute and chronic cocaine administration. Pharmacol Biochem Behav 39 (1991) 923-927
189. Veldhuis J.D., Worgul T.J., Monsaert R., and Hammond J.M. A possible role of endogenous opioids in the control of prolactin and luteinizing-hormone secretion in the human. J Endocrinol Invest 4 (1981) 31-36
190. Veldhuis J.D., Rogol A.D., and Johnson M.L. Endogenous opiates modulate the pulsatile secretion of biologically active luteinizing hormone in man. J Clin Invest 72 (1983) 2031-2040
191. Vescovi P.P., Gerra G., Maninetti L., Pedrazzoni M., Michelini M., Pioli G., et al. Metyrapone effects on beta-endorphin, ACTH and cortisol levels after chronic opiate receptor stimulation in man. Neuropeptides 15 (1990) 129-132
192. Walker Q.D., Francis R., Cabassa J., and Kuhn C.M. Effect of ovarian hormones and estrous cycle on stimulation of the hypothalamo-pituitary-adrenal axis by cocaine. J Pharmacol Exp Ther 297 (2001) 291-298
193. Weiner R.I., Findell P.R., and Kordon C. Role of classic and peptide neuromediators in the neuroendocrine regulation of LH and prolactin. In: Knobil E., and Neill J. (Eds). The Physiology of reproduction (1988), Raven Press, New York 1235-1281
194. Wood R.I. Reinforcing aspects of androgens. Physiol Behav 15 83(2) (2004) 279-289
195. Woolverton W.L., and Johnson KM. Neurobiology of cocaine abuse. Trends Pharmacol Sci 13 (1992) 193-200
196. Xu R.K., Chen L., Li H., Yang S.J., and Huang X.Y. Effects of kappa-opiate receptor antagonist MR-2266-BS on ACTH and prolactin release. Sheng Li Xue Bao 41 (1989) 395-401
197. Yang G.S., Wang W., Wang Y.M., Chen Z.D., Wang S., and Fang J.J. Effect of cocaine on germ cell apoptosis in rats at different ages. Asian J Androl 8 (2006) 569-575
198. Yen S.S.C. The synthesis and metabolism of steroid hormones. In: Strauss III J.F., and Barbieri R.L. (Eds). Yen and Jaffe's reproductive endocrinology: physiology, pathophysiology, and clinical management (2004), Elsevier Saunders, Philadelphia 149
199. Yilmaz B., and Gilmore D.P. Effects of mu, kappa, and delta opioid receptor agonists and antagonists on rat hypothalamic noradrenergic neurotransmission. Brain Res Bull 48 (1999) 491-495
200. Yilmaz B., and Gilmore D.P. Opioid modulation of hypothalamic catecholaminergic neurotransmission and the pre-ovulatory LH surge in the rat. Neuro Endocrinol Lett 20 (1999) 115-121
201. Zacny J.P., Conley K., and Galinkin J. Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers. J Pharmacol Exp Ther 282 (1997) 1187-1197
202. Zhang Q., and Gallo R.V. Effect of prodynorphin-derived opioid peptides on the ovulatory luteinizing hormone surge in the proestrous rat. Endocrine 18 (2002) 27-32
203. Zheng S.X., Bosch M.A., and Ronnekleiv O.K. mu-opioid receptor mRNA expression in identified hypothalamic neurons. J Comp Neurol 487 (2005) 332-344